Milsaperidone (VHX-896) vs Paliperidone (Invega)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Paliperidone (Invega)
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT04478838 (registry estimate)
Reported efficacy
Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)
Result source: NCT04072575
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Milsaperidone (VHX-896) | Paliperidone (Invega) |
|---|---|---|
| PANSS total, change | —Not reported | -9.8 vs -7.9−1.9 vs placeboNCT005183238 other results
|
| CGI-S, change | —Not reported | 0 vs 0±0 vs placeboNCT005183237 other results
|
| PANSS response | —Not reported | 76.8% vs 81.6%vs AripiprazoleNCT010090471 other result
|
| PSP, change | —Not reported | 17.1 vs 17.1vs AripiprazoleNCT010090473 other results
|
| Relapse (% of patients) | —Not reported | —Not posted · NCT03485417 |
PANSS total, change
- Milsaperidone (VHX-896)
- —Not reported
- Paliperidone (Invega)
- -9.8 vs -7.9−1.9 vs placeboNCT00518323
8 other results
- -17.3 vs -7.9 NCT00518323
- -13.8 vs -7.9 NCT00518323
- -9.1 vs 3.8 NCT00396565
- -19.3 vs -19.8 NCT01009047
- -25.6 vs -26.8 NCT01009047
- -13.5 vs -16.6 NCT00645099
- -15 vs -11.7 NCT00524043
- -8.9 vs -11.7 NCT00524043
CGI-S, change
- Milsaperidone (VHX-896)
- —Not reported
- Paliperidone (Invega)
- 0 vs 0±0 vs placeboNCT00518323
7 other results
- -1 vs 0 NCT00518323
- -1 vs 0 NCT00518323
- -0.4 vs 0.2 NCT00396565
- -1 vs -1 NCT01009047
- -1 vs -1 NCT01009047
- -0.5 vs -1 NCT00524043
- 0 vs -1 NCT00524043
PANSS response
- Milsaperidone (VHX-896)
- —Not reported
- Paliperidone (Invega)
- 76.8% vs 81.6%vs AripiprazoleNCT01009047
1 other result
- 67.9% vs 76.3% NCT01009047
PSP, change
- Milsaperidone (VHX-896)
- —Not reported
- Paliperidone (Invega)
- 17.1 vs 17.1vs AripiprazoleNCT01009047
3 other results
- 12.2 vs 12.2 NCT01009047
- 5.7 vs 1.6 NCT00524043
- 2.9 vs 1.6 NCT00524043
Relapse (% of patients)
- Milsaperidone (VHX-896)
- —Not reported
- Paliperidone (Invega)
- —Not posted · NCT03485417
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Paliperidone (Invega): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Paliperidone (Invega) |
|---|---|
| Dropout rate | 41.2%a NCT00784238 · Phase 4 · registry result, not featured evidence show 35 more results48.4% NCT00761579 · Phase 4 · registry result, not featured evidence 36.4% NCT00761605 · Phase 4 · registry result, not featured evidence 20% NCT01387542 · Phase 4 · registry result, not featured evidence 11.3% NCT01362439 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Extension Phase NCT01010776 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Main Phase NCT01010776 · Phase 4 · registry result, not featured evidence 32.6% NCT01724359 · Phase 4 · registry result, not featured evidence 27.1% NCT01577186 · Phase 4 · registry result, not featured evidence 40.5% NCT00757705 · Phase 4 · registry result, not featured evidence 27.8% NCT01577160 · Phase 4 · registry result, not featured evidence —Paliperidone ER Phase NCT00535145 · Phase 4 · registry result, not featured evidence 25.4%Study Treatment NCT00535145 · Phase 4 · registry result, not featured evidence —TAU - Pali ER NCT00535145 · Phase 4 · registry result, not featured evidence 40%6 mg NCT00524043 · Phase 4 · registry result, not featured evidence 47%1.5 mg NCT00524043 · Phase 4 · registry result, not featured evidence 0%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 0%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —Paliperidone DB/Paliperidone Open- NCT01662310 · Phase 3 · registry result, not featured evidence —Paliperidone: Double Blind (DB) Ph NCT01662310 · Phase 3 · registry result, not featured evidence 36.4%Paliperidone (Double-blind)/Palipe NCT00488319 · Phase 3 · registry result, not featured evidence 50.2%Paliperidone (No Double-blind)/Pal NCT00488319 · Phase 3 · registry result, not featured evidence 38.5%Placebo/Paliperidone NCT00488319 · Phase 3 · registry result, not featured evidence 24.8% NCT01009047 · Phase 3 · registry result, not featured evidence 19.1% NCT01541371 · Phase 3 · registry result, not featured evidence 50% NCT00473434 · Phase 3 · registry result, not featured evidence 20.4% NCT00566631 · Phase 3 · registry result, not featured evidence — NCT00645099 · Phase 3 · registry result, not featured evidence 28.3%Paliperidone ER: Lack of Efficacy NCT01662648 · Phase 3 · registry result, not featured evidence 29.8%Paliperidone ER: Lack of Tolerabil NCT01662648 · Phase 3 · registry result, not featured evidence 22.9%Pali ER High NCT00518323 · Phase 3 · registry result, not featured evidence 35.2%Pali ER Low NCT00518323 · Phase 3 · registry result, not featured evidence 16.7%Pali ER Medium NCT00518323 · Phase 3 · registry result, not featured evidence 15.4% NCT01606228 · Phase 3 · registry result, not featured evidence 45.4% NCT01561898 · Phase 3 · registry result, not featured evidence 35.3% NCT00396565 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 4.8%a NCT00784238 · Phase 4 · registry result, not featured evidence show 35 more results5.3% NCT00761579 · Phase 4 · registry result, not featured evidence 6.7% NCT00761605 · Phase 4 · registry result, not featured evidence 7.5% NCT01387542 · Phase 4 · registry result, not featured evidence 0.8% NCT01362439 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Extension Phase NCT01010776 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Main Phase NCT01010776 · Phase 4 · registry result, not featured evidence 10.5% NCT01724359 · Phase 4 · registry result, not featured evidence 4.8% NCT01577186 · Phase 4 · registry result, not featured evidence 6.4% NCT00757705 · Phase 4 · registry result, not featured evidence 2.5% NCT01577160 · Phase 4 · registry result, not featured evidence —Paliperidone ER Phase NCT00535145 · Phase 4 · registry result, not featured evidence 2.6%Study Treatment NCT00535145 · Phase 4 · registry result, not featured evidence —TAU - Pali ER NCT00535145 · Phase 4 · registry result, not featured evidence 2.9%6 mg NCT00524043 · Phase 4 · registry result, not featured evidence 10.6%1.5 mg NCT00524043 · Phase 4 · registry result, not featured evidence —PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —Paliperidone DB/Paliperidone Open- NCT01662310 · Phase 3 · registry result, not featured evidence —Paliperidone: Double Blind (DB) Ph NCT01662310 · Phase 3 · registry result, not featured evidence 1.7%Paliperidone (Double-blind)/Palipe NCT00488319 · Phase 3 · registry result, not featured evidence 9.5%Paliperidone (No Double-blind)/Pal NCT00488319 · Phase 3 · registry result, not featured evidence 2.6%Placebo/Paliperidone NCT00488319 · Phase 3 · registry result, not featured evidence 4.4% NCT01009047 · Phase 3 · registry result, not featured evidence 3.7% NCT01541371 · Phase 3 · registry result, not featured evidence 4.7% NCT00473434 · Phase 3 · registry result, not featured evidence 3.1% NCT00566631 · Phase 3 · registry result, not featured evidence — NCT00645099 · Phase 3 · registry result, not featured evidence 8.3%Paliperidone ER: Lack of Efficacy NCT01662648 · Phase 3 · registry result, not featured evidence 6.2%Paliperidone ER: Lack of Tolerabil NCT01662648 · Phase 3 · registry result, not featured evidence 2.1%Pali ER High NCT00518323 · Phase 3 · registry result, not featured evidence 1.9%Pali ER Low NCT00518323 · Phase 3 · registry result, not featured evidence 2.1%Pali ER Medium NCT00518323 · Phase 3 · registry result, not featured evidence 0.5% NCT01606228 · Phase 3 · registry result, not featured evidence 14.4% NCT01561898 · Phase 3 · registry result, not featured evidence 3.7% NCT00396565 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 7.3%a NCT00784238 · Phase 4 · registry result, not featured evidence show 35 more results12.1% NCT00761579 · Phase 4 · registry result, not featured evidence 9.8% NCT00761605 · Phase 4 · registry result, not featured evidence 2.5% NCT01387542 · Phase 4 · registry result, not featured evidence 0.8% NCT01362439 · Phase 4 · registry result, not featured evidence 1.9%Paliperidone ER - Extension Phase NCT01010776 · Phase 4 · registry result, not featured evidence 6.5%Paliperidone ER - Main Phase NCT01010776 · Phase 4 · registry result, not featured evidence 7.4% NCT01724359 · Phase 4 · registry result, not featured evidence 7.7% NCT01577186 · Phase 4 · registry result, not featured evidence 3.7% NCT00757705 · Phase 4 · registry result, not featured evidence 0% NCT01577160 · Phase 4 · registry result, not featured evidence 2.4%Paliperidone ER Phase NCT00535145 · Phase 4 · registry result, not featured evidence —Study Treatment NCT00535145 · Phase 4 · registry result, not featured evidence 0%TAU - Pali ER NCT00535145 · Phase 4 · registry result, not featured evidence 7.1%6 mg NCT00524043 · Phase 4 · registry result, not featured evidence 10.6%1.5 mg NCT00524043 · Phase 4 · registry result, not featured evidence 4%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 3.1%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 4.3%Paliperidone DB/Paliperidone Open- NCT01662310 · Phase 3 · registry result, not featured evidence 3.1%Paliperidone: Double Blind (DB) Ph NCT01662310 · Phase 3 · registry result, not featured evidence 3.4%Paliperidone (Double-blind)/Palipe NCT00488319 · Phase 3 · registry result, not featured evidence 18.9%Paliperidone (No Double-blind)/Pal NCT00488319 · Phase 3 · registry result, not featured evidence 23.1%Placebo/Paliperidone NCT00488319 · Phase 3 · registry result, not featured evidence 6.2% NCT01009047 · Phase 3 · registry result, not featured evidence 0.2% NCT01541371 · Phase 3 · registry result, not featured evidence 42.2% NCT00473434 · Phase 3 · registry result, not featured evidence 7.8% NCT00566631 · Phase 3 · registry result, not featured evidence 8.8% NCT00645099 · Phase 3 · registry result, not featured evidence 6.8%Paliperidone ER: Lack of Efficacy NCT01662648 · Phase 3 · registry result, not featured evidence 4.9%Paliperidone ER: Lack of Tolerabil NCT01662648 · Phase 3 · registry result, not featured evidence 2.1%Pali ER High NCT00518323 · Phase 3 · registry result, not featured evidence 3.7%Pali ER Low NCT00518323 · Phase 3 · registry result, not featured evidence 2.1%Pali ER Medium NCT00518323 · Phase 3 · registry result, not featured evidence 2.1% NCT01606228 · Phase 3 · registry result, not featured evidence — NCT01561898 · Phase 3 · registry result, not featured evidence 3% NCT00396565 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | a akathisia 8.3% extrapyramidal disorder 4.8% insomnia 4.8% NCT00784238 · Phase 4 · registry result, not featured evidence show 33 more resultsakathisia 18.4% weight increased 15.3% muscle rigidity 7.4% NCT00761579 · Phase 4 · registry result, not featured evidence insomnia 12.4% akathisia 11.4% weight increased 9.3% NCT00761605 · Phase 4 · registry result, not featured evidence drowsiness 15% headache 15% insomnia 12.5% NCT01387542 · Phase 4 · registry result, not featured evidence insomnia 3% weight increase 3% extrapyramidal symptoms 2.3% NCT01362439 · Phase 4 · registry result, not featured evidence weight increased 12.6% insomnia 8.8% depression 4.4% NCT01010776 · Phase 4 · registry result, not featured evidence insomnia 14.9% anxiety 10.7% weight increased 10.7% NCT01010776 · Phase 4 · registry result, not featured evidence insomnia 25.3% akathisia 23.2% parkinsonism 15.8% NCT01724359 · Phase 4 · registry result, not featured evidence extrapyramidal disorder 11.7% upper respiratory tract infection 6.7% tremor 4.8% NCT01577186 · Phase 4 · registry result, not featured evidence insomnia 20.7% extrapyramidal disorder 13.7% anxiety 11.7% NCT00757705 · Phase 4 · registry result, not featured evidence insomnia 15.9% constipation 11.3% extrapyramidal disorder 9.6% NCT01577160 · Phase 4 · registry result, not featured evidence weight increased 6% headache 3.6% akathisia 2.4% NCT00535145 · Phase 4 · registry result, not featured evidence 6 mg headache 11.4% (placebo 15.6%) insomnia 10% (placebo 9.4%) tremor 10% (placebo 3.1%) NCT00524043 · Phase 4 · registry result, not featured evidence 1.5 mg insomnia 13.6% (placebo 9.4%) dizziness 7.6% (placebo 1.6%) headache 7.6% (placebo 15.6%) NCT00524043 · Phase 4 · registry result, not featured evidence constipation 9.1% insomnia 9.1% somnolence 8.1% NCT00535132 · Phase 4 · registry result, not featured evidence insomnia 9.2% headache 8.2% constipation 6.1% NCT00535132 · Phase 4 · registry result, not featured evidence constipation 4.3% (placebo 3.4%) akathisia 2.1% (placebo 5.1%) headache 2.1% (placebo 1.7%) NCT01662310 · Phase 3 · registry result, not featured evidence akathisia 4.7% (placebo 5.1%) nausea 3.1% (placebo 0%) tremor 3.1% (placebo 0%) NCT01662310 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.3% somnolence 15.3% tremor 10.2% NCT00488319 · Phase 3 · registry result, not featured evidence weight increased 24.3% headache 18.9% somnolence 18.5% NCT00488319 · Phase 3 · registry result, not featured evidence somnolence 25.6% insomnia 17.9% anxiety 10.3% NCT00488319 · Phase 3 · registry result, not featured evidence akathisia 11.5% headache 10.6% somnolence 10.6% NCT01009047 · Phase 3 · registry result, not featured evidence akathisia 18.4% tremor 12.9% dystonia 8.7% NCT01541371 · Phase 3 · registry result, not featured evidence insomnia 15.6% headache 10.9% akathisia 9.4% NCT00473434 · Phase 3 · registry result, not featured evidence insomnia 23.1% tachycardia 8.5% headache 7.5% NCT00566631 · Phase 3 · registry result, not featured evidence insomnia 9.6% weight increased 9.6% headache 4.6% NCT00645099 · Phase 3 · registry result, not featured evidence insomnia 9.8% extrapyramidal disorder 6.6% headache 4.5% NCT01662648 · Phase 3 · registry result, not featured evidence insomnia 11.6% headache 4.1% nausea 3.9% NCT01662648 · Phase 3 · registry result, not featured evidence somnolence 20.8% (placebo 2%) akathisia 16.7% (placebo 0%) insomnia 12.5% (placebo 21.6%) NCT00518323 · Phase 3 · registry result, not featured evidence headache 9.3% (placebo 3.9%) insomnia 9.3% (placebo 21.6%) schizophrenia 9.3% (placebo 7.8%) NCT00518323 · Phase 3 · registry result, not featured evidence somnolence 14.6% (placebo 2%) akathisia 8.3% (placebo 0%) tremor 8.3% (placebo 0%) NCT00518323 · Phase 3 · registry result, not featured evidence insomnia 13.3% anemia 4.8% acute psychotic symptoms 1.6% NCT01606228 · Phase 3 · registry result, not featured evidence schizophrenia 16.4% (placebo 42.8%) insomnia 11.2% (placebo 10.1%) nasopharyngitis 10.4% (placebo 8%) NCT00396565 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Paliperidone (Invega)
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 3 more results
show 2 more results
show 2 more results
show 25 more results
+ 69 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Paliperidone (Invega)'s landscape